Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17621259 | 0.98 | ALDH1A1 (0.30) | ALDH1A1KMT2A | |
| SCHEMBL22578076 | 0.90 | — | — | |
| SCHEMBL23385650 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL29656295 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL785938 | 0.72 | POLB (0.33) | KMT2A | |
| SCHEMBL22470021 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL31438389 | 0.69 | — | — | |
| SCHEMBL11271542 | 0.69 | — | — | |
| SCHEMBL5086353 | 0.69 | — | — | |
| SCHEMBL17457173 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182426-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2024-06-06 | — | — | US | disclosed |
| US-11512053-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9598374-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598374-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512053-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
| US-20240182426-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ALDH1A1 686/4885KMT2A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.